Purpose: To evaluate the effect of teriparatide (TPTD) on bone mineral density (BMD) and bone markers under clinical practice conditions. To assess whether the results in real-life match those published in clinical trials.
Methods: Cross-sectional study of postmenopausal women treated with TPTD for at least 12 months.